immatics biotechnologies GmbH to Present at CIMT Annual Meeting 2013 in Mainz, Germany
Tuebingen, 13. May 2013 - immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announces today that the Company will make a number of presentations on its therapeutic cancer vaccine research at the Association for Cancer Immunotherapy (CIMT) Annual Meeting 2013 (14-16 May) in Mainz, Germany. CIMT is Europe’s largest meeting focused on cancer immunotherapy research and development.
Details of the presentations are as follow:
Session: CIP Breakout Workshop
Type: Talk
Presentation title: MDSC update
Date: Tuesday, 14 May, 3pm – 5pm CET
Presenter: Steffen Walter, immatics biotechnologies GmbH, Germany
Location: Hall C
Session: Short Talk Session III / Immunomonitoring
Type: Talk
Presentation title: A novel clinically validated method to predict T-cell epitope immunogenicity for cancer vaccine development
Date: Wednesday, 15 May, 11.15am – 11.30am CET
Abstract number: 056
Presenter: Sarah Kutscher, immatics biotechnologies GmbH, Germany
Location: Hall C
Session: Plenary Session 6 / Regulatory Research
Type: Talk
Presentation title: Immunomonitoring regulation – A user’s perspective
Date: Thursday, 16 May, 11.20am – 11.45am
Presenter: Steffen Walter, immatics biotechnologies, CIMT-CIP (Tuebingen, Germany)
Session Chair: Harpreet Singh (immatics, Tuebingen, Germany), Cedrik Britten (Ribological, Mainz, Germany)
Location: Hall A
In addition, immatics will make poster presentations, as follow:
Tuesday, 14 May, 3pm – 5.30pm
Wednesday, 15 May, 4pm – 5.30pm
Abstract number: 56
A novel clinically validated method to predict T-cell epitope immunogenicity for cancer vaccine development Abstract number: 169
Two alternative variants from human hydin are cancer-associated antigens
Abstract number: 215
The Glioma Actively Personalized Vaccine Consortium (GAPVAC)
For additional information on immatics please visit www.immatics.com or contact:
Paul Higham, CEO
Dr. Nikola Wiegeler, Assistant to the Management
immatics biotechnologies GmbH
Phone: +49 7071 5397 110
E-mail: media@immatics.com
Citigate Dewe Rogerson
David Dible / Chris Gardner / Sita Shah
Phone: +44 207 638 9571
E-mail: david.dible@citigatedr.co.uk
About immatics
immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901, is in a pivotal phase 3 study after completing a successful randomized phase 2 trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, which has reported improved overall survival data in patients with advanced colorectal cancer (phase 1/2 study completed), and IMA950, which is in phase 1 in patients with glioma.
immatics’ unique technology platform XPRESIDENTTM discovers novel relevant cancer antigens known to be expressed on tumor cells, tumor-associated peptides (TUMAPs), as the basis for its vaccines. In contrast to widely used existing in silico and indirect methods to identify peptide antigens immatics’ TUMAPs are confirmed to be naturally expressed in primary cancer tissue. TUMAPs activate white blood cells (so called cytotoxic T cells) against tumor cells.
immatics’ vaccines contain multiple TUMAPs to maximize the chances of clinical success by increasing the number of targets on cancer cells that they address. Phase 2 results with IMA901 and IMA910 have shown significantly better survival in patients who respond to multiple TUMAPs in both of these vaccines.
immatics’ multi-peptide vaccines are ‘drug like’, i.e. fully synthetic, off-the-shelf, easily scalable and stable. immatics is based in Tuebingen and Martinsried (Munich), Germany.
Help employers find you! Check out all the jobs and post your resume.